Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept long-term safety extension in pediatric JIA subtypes
NL-OMON37419Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of etanercept in juvenile idiopathic arthritis (JIA), juvenile idiopathic arthritis, enthesitis-related (JIA-ERA) and psoriatic arthritis (PsA) (2 arms), sponsored by Pfizer. Primary endpoint: Occurrence of malignancy. Started May 2012; status: active, not recruiting.
02
Drugs
etanercept
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON37419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37419.